

Telemedicine in Urology Cancer Hospital: A Retrospective Review of 420 Patients

Paulo Mazzo Calzavara¹ Fernando Terziotti² Daniel Crippa da Silva² Augusto Varella Postiglioni² Matheus Mehret Moleta² Andréa Graciano Bianconi² Fellipe Danciger Alves de Magalhães² Arnold Peter Paul Achermann² Gabriella Paslar Carbonieri¹ Manuela Perri Marin¹

1. Estudante Medicina na Pontifícia Universidade Católica do Paraná – Campus Londrina 2. Hospital Evangélico de Londrina-PR

Introduction:

Telemedicine emerges as a powerful tool for healthcare accessibility, improving connecting remote areas with central healthcare services. In Brazil, telemedicine regulations were implemented in response to the Covid-19 pandemic, aiming to reduce in-person visits and minimize virus transmission. The widespread adoption telemedicine during the pandemic, driven by the goal of ensuring safety, reveals its broader potential beyond the crisis.

Purpose:

This paper focuses on evaluating telemedicine in urology during the pandemic, analyzing data from 420 virtual consultations to assess effectiveness, challenges, demographic characteristics, encountered obstacles, and the need for in-person care.

Methods:

We performed a retrospective review of 420 urological telemedicine consultations during the COVID-19 pandemic at a tertiary cancer hospital, conducted from June 3rd, 2020, to July 14th, 2021, after ethic institutional review board approval. The study focused on a single urologist assessing patients with urological cancer diagnoses. Data collected included age, gender, distance from the hospital, neoplasm diagnosis, encountered difficulties, unsuccessful calls, and conversions to inperson care when required physical examination or technical difficulties.

| Telemedicine | n=420 (100%) |
|--------------------------|--------------|
| Lack of laboratory exams | 36 (8.6%) |
| Lack of imaging exams | 17 (4.1%) |
| Unsuccessful phone call | 24 (5.7%) |
| Not found at home | 8 (1.9%) |
| Not answered phone call | 12 (2.9%) |
| Technical problems | 4 (1%) |
| Not found at home | 2 (0.5%) |

Table 2 – Difficulties observed during Telemedicine assessment Data are expressed as absolute number (%)

Results:

Results show that most patients were male $(92.1\% \ vs \ 7.9\%)$, aged $71 \ (67-78)$ years, with prostate cancer as the predominant diagnosis (78.3%), follow by bladder cancer (8,8%) and kidney cancer (6,9%). They were primarily undergoing post-treatment follow-up $(92.4\% \ vs \ 7,6\%)$ and residing at a median distance of $74 \ (15-96)$ km from the hospital. Challenges included the lack of laboratory (8,6%) and imaging exams (4,1%), along with unsuccessful phone calls (5,7%) and technical issues (1%). Nine patients (2.14%) required a conversion to in-person care, mainly due to the need for physical examinations or medical procedures. Just one patient opts to conversion for in-person care.

Conclusion:

Telemedicine successfully provided urological care to oncologic patients, with technical difficulties and the need for physical examinations being the main reasons for conversion to in-person assessments.

References:

1. Hollander JE. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2. Brasil. Lei no 13.989, de 15 de abril de 2020. Diário Oficial da União. 3. Keesara S. Covid-19 and Health Care's Digital Revolution. N Engl J Med. 4. Rodriguez Socarrás M. Telemedicine and Smart Working: Recommendations of the European Association of Urology. European Urology. 5. Sosnowski R. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. European Urology. 6. Symeonidis EN. Telemedicine in Urology: Where Have We Been and Where Are We Heading? European Urology Open Science. 7. Dorsey ER. State of Telehealth. N Engl J Med. 8. Rodler S. Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? European Urology Focus. 9. Nourian A. A 5-Year Single-Institution Experience Integrating Telehealth into Urologic Care Delivery. Telemedicine and e-Health. 10. Gadzinski AJ. Telehealth in urology after the COVID-19 pandemic. Nat Rev Urol.